Infectious complications after allo-HSCT in early and late recovering patients
| Complications . | Early, n = 19 [n (%)] . | Late, n = 17 [n (%)] . | Rituximab, n = 4 [n (%)] . |
|---|---|---|---|
| Bacterial diseases | |||
| Sepsis | 9 (47) | 8 (47) | 4 (100) |
| Pneumonia | 2 (11) | 5 (29) | 2 (50) |
| Viral diseases | |||
| BK virus cystitits | 1 (5) | 3 (18) | 2 (50) |
| VZV | 1 (5) | 1 (6) | 1 (25) |
| HSV | 3 (16) | 1 (6) | 0 (0) |
| Complications . | Early, n = 19 [n (%)] . | Late, n = 17 [n (%)] . | Rituximab, n = 4 [n (%)] . |
|---|---|---|---|
| Bacterial diseases | |||
| Sepsis | 9 (47) | 8 (47) | 4 (100) |
| Pneumonia | 2 (11) | 5 (29) | 2 (50) |
| Viral diseases | |||
| BK virus cystitits | 1 (5) | 3 (18) | 2 (50) |
| VZV | 1 (5) | 1 (6) | 1 (25) |
| HSV | 3 (16) | 1 (6) | 0 (0) |
BK virus, member of human polyomavirus; Early, patients with early recovering B cells; HSV, Herpes simplex virus; Late, patients with late recovering B cells; Rituximab, patients, who received Rituximab treatment after EBV reactivation post allo-HSCT; VZV, Varicella zoster virus.